
Releases
Insilico Medicine Projects Triple-Digit Revenue Surge for Mid-2026
Generating revenue between USD 102.5 million and USD 106.5 million, Insilico Medicine has issued a positive profit alert for the first half of 2026. This performance, reflecting a year-on-year growth of up to 287%, marks a significant financial milestone for the AI-driven clinical-stage biotechnology firm.
























